| Literature DB >> 36038958 |
Hyeonseong Woo1, Sanghee Lee1, Hyun Sung Lee1, Hyun Jun Chae1, Jongtak Jung2, Myung Jin Song2, Sung Yoon Lim2, Yeon Joo Lee2, Young-Jae Cho2, Eu Suk Kim2, Hong Bin Kim2, Jae-Young Lim1, Kyoung-Ho Song3, Jaewon Beom4.
Abstract
BACKGROUND: This study aimed to investigate the effects of comprehensive rehabilitation management on functional recovery and examine the correlation between clinical parameters and improvements in functional outcomes in severe-to-critical inpatients with coronavirus disease 2019 (COVID-19) in a tertiary hospital.Entities:
Keywords: Coronavirus Disease 2019 (COVID-19); Critical Illness; Outcome Assessment; Recovery of Function; Rehabilitation
Mesh:
Year: 2022 PMID: 36038958 PMCID: PMC9424699 DOI: 10.3346/jkms.2022.37.e262
Source DB: PubMed Journal: J Korean Med Sci ISSN: 1011-8934 Impact factor: 5.354
Fig. 1Comprehensive rehabilitation with multi-component assessment and management.
COVID-19 = coronavirus disease 2019, MMSE = Mini-Mental Status Examination, PHQ-9 = Patient Health Questionnaire-9, VFSS = videofluoroscopic swallowing study.
Baseline characteristics of the 37 included patients
| Parameters | Values | ||
|---|---|---|---|
| Demographic factors | |||
| Age at onset, yr | 64.1 ± 12.7 | ||
| Male | 23 (62.2) | ||
| BMI, kg/m2 | 24.2 ± 4.9 | ||
| History of pulmonary diseases | 5 (13.5) | ||
| Charlson comorbidity index | |||
| None | 17 (45.9) | ||
| Mild comorbidity (CCI, 1–2) | 14 (37.8) | ||
| Moderate comorbidity (CCI, 3–4) | 5 (13.5) | ||
| Severe comorbidity (CCI ≥ 5) | 1 (2.7) | ||
| COVID-19-related factors | |||
| Combined bacterial pneumonia | 26 (70.3) | ||
| Complication (AKI, HF, SICMP, pneumothorax, or sepsis) | 23 (62.2) | ||
| APACHE II score | 12.8 ± 5.1 | ||
| WHO ordinal scale | |||
| 5 (Non-invasive ventilation or high-flow oxygen) | 3 (8.1) | ||
| 6 (Intubation and mechanical ventilation) | 22 (59.5) | ||
| 7 (Intubation and additional organ support, e.g., ECMO, RRT, and vasopressors) | 12 (32.4) | ||
| Total length of hospital stay, days | 63.8 ± 36.5 | ||
| Length of ICU stay, days | 33.6 ± 23.9 | ||
| Quarantine period, days | 31.0 ± 11.5 | ||
| Duration of mechanical ventilation, days | 33.8 ± 31.8 | ||
| Duration of high-flow oxygen therapy, days | 6.0 ± 6.1 | ||
| Tracheostomy | 18 (48.6) | ||
| ECMO | 12 (32.4) | ||
| Antiviral treatment on COVID-19 | 32 (86.5) | ||
| Remdesivir | 28/32 (87.5) | ||
| Lopinavir/ritonavir | 4/32 (12.5) | ||
| Use of systemic corticosteroid | 36 (97.3) | ||
| Dexamethasone ≥ 6 mg (or methylprednisolone 30 mg) daily, for ≥ 5 days | 30/36 (83.3) | ||
| Low-dose dexamethasone (< 6 mg daily), for ≥ 5 days | 6/36 (16.7) | ||
| Use of neuromuscular-blocking agents | |||
| Continuous infusion of cisatracurium (2–4 mcg/kg/min) or rocuronium (0.2–0.5 mg/kg/h) for ≥ 5 days) | 13 (35.1) | ||
| WBC at the beginning of rehabilitation, cells/µL | 9,741.6 ± 3,734.0 | ||
| CRP at the beginning of rehabilitation, mg/dL | 2.6 ± 3.5 | ||
| Oxygen demand at the beginning of rehabilitation, L/min | 1.6 ± 2.0 | ||
| Exercise program | |||
| Site of exercise program | |||
| Bedside | 4 (10.8) | ||
| PT room | 12 (32.4) | ||
| PT room and bedside | 21 (56.8) | ||
| Number of days (hr) of PT room program | 8.3 ± 6.7 days (7.2 ± 6.2 hours) | ||
| Number of days (hr) of bedside program | 6.9 ± 9.7 days (1.3 ± 1.7 hours) | ||
| Nutritional assessment and management | |||
| Consultation with dietitians | 34 (91.9) | ||
| Ideal body weight, kg | 59.2 ± 7.6 (n = 34) | ||
| Albumin, g/dL | 3.1 ± 0.4 | ||
| Malnutrition | |||
| Mild | 16 (43.2) | ||
| Mild-to-moderate | 5 (13.5) | ||
| Moderate | 4 (10.8) | ||
| Moderate-to-severe | 1 (2.7) | ||
| None | 8 (21.6) | ||
| Not evaluated | 3 (8.1) | ||
| Target daily intake of protein, g/kg | 1.3 ± 0.1 (n = 34) | ||
| VFSS performed | 16 (43.2) | ||
| Penetration or aspiration observed in VFSS findings | 13/16 (81.3) | ||
| Penetration–Aspiration Scale of most severely aspirated diet | 3.6 ± 2.3 | ||
| Swallowing rehabilitation | 14 (37.8) | ||
| Psychological assessment and management | |||
| Consultation with psychiatrist | 28 (75.7) | ||
| Antidepressant or antipsychotic drugs (for ≥ 3 days) | 26 (70.3) | ||
| MMSE at baseline | 25.0 ± 4.9 (n = 27) | ||
| MMSE at discharge | 27.4 ± 3.2 (n = 23) | ||
| PHQ-9 at baseline | 6.3 ± 5.0 (n = 18) | ||
| PHQ-9 at discharge | 4.4 ± 4.6 (n = 13) | ||
Continuous parameters are presented as mean ± standard deviation and categorical parameters are presented as numbers (%).
BMI = body mass index, CCI = Charlson comorbidity index, COVID-19 = coronavirus disease 2019, AKI = acute kidney injury, HF = heart failure, SICMP = stress-induced cardiomyopathy, APACHE II = Acute Physiology and Chronic Health Evaluation II, WHO = World Health Organization, ECMO = extracorporeal membrane oxygenation, RRT = renal replacement therapy, ICU = intensive care unit, WBC = white blood cell count, CRP = C-reactive protein, PT = physiotherapy, VFSS = videofluoroscopic swallow study, MMSE = Mini-Mental Status Examination, PHQ-9 = Patient Health Questionnaire-9.
Comparison of outcome parameters at baseline, discharge, and 1-month OPD follow-up
| Outcome | Baseline | Discharge | 1-Month OPD follow-up | |
|---|---|---|---|---|
| MRC sum score | 44 (36.5–48) | 48 (45–48) | 48 (45.5–57.5) | < 0.001 |
| Hand grip strength, lb | 55 (28–96) | 60 (40–100) | 70 (55–106) | < 0.001 |
| No. of 1-min sit-to-stand | 0 (0–6) | 12 (0–18) | 20 (0–23) | 0.008 |
| Gait speed, m/s | 0.00 (0.00–0.00) | 0.43 (0.30–0.67) | 0.94 (0.70–1.09) | < 0.001 |
| Functional Ambulation Classification | 0 (0–2) | 3 (2–4) | 5 (4–5) | < 0.001 |
| Berg Balance Scale | 6 (2–24) | 41 (34–50) | 51 (47–53) | < 0.001 |
Values are presented as median (interquartile range).
OPD = outpatient department, MRC = Medical Research Council.
Skeletal muscle mass index and body fat mass between in-hospital and 1-month follow-up assessment
| Outcome | In-hospital | 1-Month OPD follow-up | |
|---|---|---|---|
| Appendicular skeletal muscle mass index (kg/m2) | 5.80 (5.39–7.05) | 6.13 (5.24–7.76) | 0.012 |
| Body fat mass (kg) | 21.8 (15.1–30.7) | 22.2 (17.6–31.2) | 0.394 |
Values are presented as median (interquartile range).
OPD = outpatient department.
Fig. 2Adjusted Spearman’s partial correlation between rehabilitation dose and improvement of outcome parameters (age, sex, Charlson comorbidity index, WHO ordinal scale used as control factors). (A) Changes in FAC from baseline to discharge showed positive associations with the number of days of rehabilitation (ρ = 0.46, P = 0.027) and (B) Changes in BBS from baseline to discharge also showed moderate correlation with the number of days of rehabilitation (ρ = 0.50, P = 0.019).
WHO = World Health Organization, FAC = Functional Ambulation Classification, BBS = Berg Balance Scale.
Correlation between rehabilitation dose and improvement of outcome parameters
| Outcome | Unadjusted Spearman’s correlation | Adjusted Spearman’s partial correlation | ||
|---|---|---|---|---|
| ρ |
| ρ |
| |
| Dose of rehabilitation – FAC | 0.48 | 0.011 | 0.46 | 0.027 |
| Dose of rehabilitation – BBS | 0.56 | 0.003 | 0.50 | 0.019 |
ρ: Spearman’s rank correlation coefficients; adjusted Spearman’s partial correlation analysis used age, sex, Charlson comorbidity index, WHO ordinal scale as control factors.
FAC = Functional Ambulation Classification, BBS = Berg Balance Scale, WHO = World Health Organization.
Correlation between improvement of functional outcomes and clinical parameters (between baseline and 1-month OPD follow-up)
| Clinical parameters | Improvements of functional outcomes | Spearman’s rank correlation coefficient | |
|---|---|---|---|
| PHQ-9 | 1-min sit-to-stand | −0.82 | 0.011 |
| PHQ-9 | Gait speed | −0.63 | 0.039 |
| Age | Gait speed | −0.53 | 0.036 |
| Total length of stay | Gait speed | −0.67 | 0.005 |
| Length of stay at ICU | Gait speed | −0.57 | 0.022 |
| Mechanical ventilation period | Gait speed | −0.56 | 0.023 |
| Tracheostomy | Gait speed | −0.62 | 0.011 |
| Albumin | Gait speed | 0.65 | 0.006 |
OPD = outpatient department, PHQ-9 = Patient Health Questionnaire-9, ICU = intensive care unit.